NVST - Envista Holdings Corporation
NYSE
->
Healthcare
->
Medical Instruments & Supplies
Brea,
United States
Type: Equity
NVST price evolution
NVST
| (in millions $) | 27 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1036.2 | $948.5 | $940 | |
| Short term investments | ||||
| Net receivables | $392.1 | $380.6 | $413 | $407.5 |
| Inventory | $265.6 | $263.8 | $267.4 | $258.8 |
| Total current assets | $1797 | $1821.9 | $1771.9 | $1743.7 |
| Long term investments | ||||
| Property, plant & equipment | $433.2 | $415.8 | $431.5 | $434.7 |
| Goodwill & intangible assets | $2981.8 | $4178.5 | $4246.2 | |
| Total noncurrent assets | $3616.2 | $4784.4 | $4861.4 | |
| Total investments | ||||
| Total assets | $5510.7 | $5438.1 | $6556.3 | $6605.1 |
| Current liabilities | ||||
| Accounts payable | $172.1 | $172.4 | $174.7 | $179.5 |
| Deferred revenue | ||||
| Short long term debt | $150.2 | $148 | $145.6 | |
| Total current liabilities | $865.5 | $821.4 | $781.3 | $780.8 |
| Long term debt | $1305.6 | $1492.5 | $1498 | $1508 |
| Total noncurrent liabilities | $1640 | $1634.7 | $1650.4 | |
| Total debt | $1642.7 | $1646 | $1653.6 | |
| Total liabilities | $2438.2 | $2461.4 | $2416 | $2431.2 |
| Shareholders' equity | ||||
| Retained earnings | -$488.6 | -$496.8 | $654.8 | $631.2 |
| Other shareholder equity | -$223.6 | -$301.6 | -$283.6 | -$217.2 |
| Total shareholder equity | $2976.7 | $4140.3 | $4173.9 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $940 | $606.9 | $1073.6 | $888.9 |
| Short term investments | ||||
| Net receivables | $407.5 | $393.5 | $331.9 | $361 |
| Inventory | $258.8 | $300.8 | $263.8 | $266.9 |
| Total current assets | $1743.7 | $1424.6 | $1835.8 | $1590.5 |
| Long term investments | ||||
| Property, plant & equipment | $434.7 | $425.4 | $392.2 | $468.3 |
| Goodwill & intangible assets | $4246.2 | $4583.3 | $4178.4 | $4689.9 |
| Total noncurrent assets | $4861.4 | $5162.4 | $4738.4 | $5285.5 |
| Total investments | ||||
| Total assets | $6605.1 | $6587 | $6574.2 | $6876 |
| Current liabilities | ||||
| Accounts payable | $179.5 | $228.3 | $185.8 | $235.1 |
| Deferred revenue | ||||
| Short long term debt | $145.6 | $537 | $456.1 | $919.3 |
| Total current liabilities | $780.8 | $1236.7 | $1208.2 | $1684.7 |
| Long term debt | $1508 | $870.7 | $1003.8 | $1061.5 |
| Total noncurrent liabilities | $1650.4 | $1143.4 | $1308 | $1470.3 |
| Total debt | $1653.6 | $1529.1 | $1459.9 | $1980.8 |
| Total liabilities | $2431.2 | $2380.1 | $2516.2 | $3155 |
| Shareholders' equity | ||||
| Retained earnings | $631.2 | $731.4 | $466.9 | $126.4 |
| Other shareholder equity | -$217.2 | -$225.1 | -$143.5 | -$91.8 |
| Total shareholder equity | $4173.9 | $4206.9 | $4057.6 | $3720.6 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $633.1 | $623.6 | $645.6 | |
| Cost of revenue | $306.5 | $267.3 | $309.7 | |
| Gross Profit | $326.6 | $356.3 | $335.9 | |
| Operating activities | ||||
| Research & development | $23.6 | $23.3 | $20.2 | |
| Selling, general & administrative | $302.5 | $284.9 | $260.2 | |
| Total operating expenses | $1479.9 | $308.2 | $538.7 | |
| Operating income | -$1153.3 | $48.1 | -$202.8 | |
| Income from continuing operations | ||||
| EBIT | -$1154.4 | $48.2 | -$201.1 | |
| Income tax expense | -$14.5 | $11.7 | $2.4 | |
| Interest expense | $11.7 | $12.9 | $13.9 | |
| Net income | ||||
| Net income | -$1151.6 | $23.6 | -$217.4 | |
| Income (for common shares) | -$1151.6 | $23.6 | -$217.4 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2566.5 | $2569.1 | $2282 | |
| Cost of revenue | $1126 | $1094.3 | $1123.9 | |
| Gross Profit | $1440.5 | $1474.8 | $1158.1 | |
| Operating activities | ||||
| Research & development | $93.8 | $100.1 | $100.8 | |
| Selling, general & administrative | $1056.9 | $1055.5 | $1024 | |
| Total operating expenses | $1409 | $1155.6 | $1124.8 | |
| Operating income | $31.5 | $319.2 | $33.3 | |
| Income from continuing operations | ||||
| EBIT | $8.5 | $327.4 | $32.4 | |
| Income tax expense | $45.3 | $45.9 | -$63.4 | |
| Interest expense | $63.4 | $38.4 | $62.5 | |
| Net income | ||||
| Net income | -$100.2 | $243.1 | $33.3 | |
| Income (for common shares) | -$100.2 | $243.1 | $33.3 | |
| (in millions $) | 27 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1151.6 | $23.6 | -$217.4 | |
| Operating activities | ||||
| Depreciation | $41.7 | $39.4 | $40 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.3 | $11 | $4.4 | |
| Total cash flows from operations | $93.1 | $40.3 | $102 | |
| Investing activities | ||||
| Capital expenditures | -$6.8 | -$11 | -$2.1 | |
| Investments | $0.4 | $0.5 | ||
| Total cash flows from investing | -$47.2 | -$5.9 | -$10.7 | -$12.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.6 | $1.3 | $3.8 | |
| Net borrowings | -$0.3 | |||
| Total cash flows from financing | -$102.8 | $0.3 | -$2.6 | $3.3 |
| Effect of exchange rate | -$2.8 | $0.2 | -$18.5 | $23.1 |
| Change in cash and equivalents | $51.3 | $87.7 | $8.5 | $115.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$100.2 | $243.1 | $340.5 | $33.3 |
| Operating activities | ||||
| Depreciation | $162.6 | $162.1 | $151.9 | $163.1 |
| Business acquisitions & disposals | -$622.3 | $310.4 | -$40.7 | |
| Stock-based compensation | $22.8 | $30.5 | $28.2 | $22.6 |
| Total cash flows from operations | $275.7 | $182.7 | $361.6 | $283.9 |
| Investing activities | ||||
| Capital expenditures | -$52.1 | -$72.4 | -$43.1 | -$42.4 |
| Investments | $12.3 | $56 | ||
| Total cash flows from investing | -$62.4 | -$657.3 | $262.7 | -$69.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $11.3 | $21.8 | $19.5 | $13.8 |
| Net borrowings | $115.4 | -$0.2 | -$478 | $479.4 |
| Total cash flows from financing | $118.9 | $12.5 | -$465.6 | $492.5 |
| Effect of exchange rate | $0.9 | -$4.6 | $26 | -$29.6 |
| Change in cash and equivalents | $333.1 | -$466.7 | $184.7 | $677.7 |
News
Fundamentals
| Market cap | $2.66B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 172.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.08 |
| Quick ratio | 1.77 |